首页> 外文期刊>Cancer Science >Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer
【24h】

Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer

机译:环氧合酶-2与人表皮生长因子受体2在人乳腺癌血管内皮生长因子C上调与淋巴管生成中的关系

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Both cyclooxygenase (COX)-2 and human epidermal growth factor receptor (HER)-2 promote breast cancer progression; however, the relationship between the two molecules remains unclear. We utilized human breast cancer tissues and cell lines to examine whether COX-2 and HER-2 played independent or interdependent roles in vascular endothelial growth factor (VEGF)-C up-regulation and lymphangiogenesis. A paired correlation of immunodetectable levels of COX-2, VEGF-C, and HER-2 proteins and lymphovascular density (LVD; D2-40-immunolabeled) in 55 breast cancer specimens revealed a positive correlation between COX-2 and HER-2 irrespective of clinicopathological status. However COX-2 alone positively correlated with LVD. In 10 independent specimens, mRNA levels showed a positive correlation between HER-2 and COX-2 or VEGF-C but not LYVE-1 (lymphovascular endothelial marker). These findings implicate COX-2, but not HER-2, in breast cancer–associated lymphangiogenesis. Manipulation of the COX-2 or HER-2 genes in breast cancer cell lines varying widely in COX-2 and HER-2 expression revealed a direct role of COX-2 and an indirect COX-2 dependent role of HER-2 in VEGF-C up-regulation: (i) high VEGF-C expression in high COX-2/low HER-2 expressing MDA-MB-231 cells was reduced by siRNA-mediated down-regulation of COX-2, but not HER-2; (ii) integration of HER-2 in these cells simultaneously up-regulated COX-2 protein as well as VEGF-C secretion; and (iii) low VEGF-C secretion by high HER-2/low COX-2 expressing SK-BR-3 cells was stimulated by COX-2 overexpression. These findings of the primary role of COX-2 and the COX-2-dependent role of HER-2, if any, in VEGF-C up-regulation and lymphangiogenesis suggest that COX-2 inhibitors may abrogate lymphatic metastasis in breast cancer irrespective of HER-2 status. (Cancer Sci 2010)
机译:环氧合酶(COX)-2和人表皮生长因子受体(HER)-2均可促进乳腺癌的发展。然而,两个分子之间的关系仍不清楚。我们利用人类乳腺癌组织和细胞系来检查COX-2和HER-2在血管内皮生长因子(VEGF)-C上调和淋巴管生成中是否起着独立或相互依赖的作用。 55个乳腺癌标本中COX-2,VEGF-C和HER-2蛋白的免疫检测水平与淋巴管密度(LVD; D2-40免疫标记)的成对相关性揭示了COX-2和HER-2呈正相关临床病理状态。但是,单独的COX-2与LVD正相关。在10个独立的标本中,mRNA水平在HER-2和COX-2或VEGF-C之间呈正相关,而与LYVE-1(淋巴管内皮标记)无关。这些发现暗示了与乳腺癌相关的淋巴管生成中的COX-2而非HER-2。在COX-2和HER-2表达差异很大的乳腺癌细胞系中对COX-2或HER-2基因的处理揭示了COX-2的直接作用以及HER-2在VEGF-中的间接COX-2依赖性作用C上调:(i)siRNA介导的COX-2下调降低了高COX-2 /低HER-2表达的MDA-MB-231细胞中VEGF-C的高表达,但未降低HER-2。 (ii)将HER-2整合到这些细胞中同时上调COX-2蛋白以及VEGF-C的分泌; (iii)通过高表达COX-2刺激高表达HER-2 /低COX-2表达的SK-BR-3细胞的低VEGF-C分泌。这些关于COX-2的主要作用和HER-2的COX-2依赖性作用(如果有的话)在VEGF-C上调和淋巴管生成中的发现表明,COX-2抑制剂可消除乳腺癌的淋巴结转移,无论HER-2状态。 (《癌症科学》 2010年)

著录项

  • 来源
    《Cancer Science》 |2010年第9期|p.2026-2032|共7页
  • 作者单位

    Departments of Anatomy and Cell Biology;

    |Departments of Anatomy and Cell Biology|Biology;

    |Departments of Anatomy and Cell Biology;

    Departments of Anatomy and Cell Biology|Oncology, The University of Western Ontario, London, Ontario, Canada;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号